Publications & Presentations Our innovative development programs are backed by sound scientific research. Filter by All Publications Data Presentations An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study Paul Thornton MD et al. Pediatric Endocrine Society (PES) 2024 NEJM Letter to the Editor: Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia Soravis Osataphan MD et al. The New England Journal of Medicine 08/23/23 Treatment Of Severe Refractory Hypoglycemia Due To Malignant Insulinoma With A Novel Anti-Insulin Receptor Antibody Soravis Osataphan MD et al. ENDO 2023 Results from a Global, Multi-Center, Phase 2b Study (RIZE) in Congenital Hyperinsulinism: Characterization of a High Unmet Treatment Need and Glycemic Response to RZ358 Hüseyin Demirbilek ESPE 2022 A Single and Repeat-Dose Study of RZ358 in Patients with Post-Gastric Bypass Hypoglycemia (PGBH): Results of Population PK/PD Modeling Yongjun Hu PhD et al. ENDO 03/20/21 Continuous Glucose Monitoring (CGM) Reveals Undertreated Hypoglycemia in Patients with Congenital Hyperinsulinism Davelyn Eaves Hood MD et al. ESPE 2021 Single Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric Patients Daniel Epling et al. Pediatric Endocrine Society (PES) 05/30/20 RZ358-606 RIZE Study: An Open-Label Multiple-Dose Study of RZ358 in Patients with Congenital Hyperinsulinism Nevan Charles Elam et al. Data Call 05/01/20 Targeting rare and metabolic diseases with transformative therapies Company Internal Biopharma Dealmakers 11/2019 Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers Kirk W. Johnson et al. The Journal of Clinical Endocrinology & Metabolism 08/2017 123
